Characterization of Circulating Tumor Cells Using Imaging Flow Cytometry in Liver Disease Patients

Hepatocellular carcinoma (HCC) is asymptomatic at an early stage which delays its timely diagnosis and treatment. Circulating tumor cells (CTCs), derived from a primary or secondary tumor, may help in the management of HCC. Here, we evaluate and characterize CTCs in liver disease patients. In total,...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical and experimental hepatology Vol. 13; no. 4; pp. 608 - 617
Main Authors Debnath, Partha, Dalal, Kruti, Dalal, Bhavik, Athalye, Shreyasi, Chandnani, Sanjay, Jain, Shubham, Shukla, Akash, Rathi, Pravin, Shankarkumar, Aruna
Format Journal Article
LanguageEnglish
Published India Elsevier B.V 01.07.2023
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Hepatocellular carcinoma (HCC) is asymptomatic at an early stage which delays its timely diagnosis and treatment. Circulating tumor cells (CTCs), derived from a primary or secondary tumor, may help in the management of HCC. Here, we evaluate and characterize CTCs in liver disease patients. In total, 65 patients, categorized into liver cirrhosis (LC) (n = 30) and HCC (n = 35), were enrolled. Using ImagestreamX MkII imaging flow cytometer, CTCs were detected and characterized using biomarker expression of EpCAM, CK, AFP, CD45, and DRAQ5 in LC and HCC patients. CTCs were detected in 33/35 (94%) HCC patients and in 28/30 (93%) LC patients. In the HCC group, the number of biomarker-positive CTCs was higher in BCLC stage D when compared with others. EpCAM + CK was the most expressed biomarker on CTCs in LC versus HCC (83.3% vs. 77.14%), followed by AFP (80% vs. 65.71%), EpCAM (30% vs. 28.57%), and CK (16.6% vs. 14.28%). The EpCAM cell area was significantly associated (P value = 0.031) with the CTC-positive status. The combination biomarker expression of CTCs cell area (EpCAM, CK, and AFP) performed well with the area under the curve of 0.92, high sensitivity, and specificity in detecting early-stage and AFP-negative HCC as well as in AFP-negative LC cases. Enumeration and cell area of CTCs may be used as a biomarker for early detection of HCC and guiding treatment. [Display omitted] •CTCs were characterized using a biomarker panel (+EpCAM, +CK, +AFP, −CD45, +DRAQ) in LC and HCC patients using IFC.•Surface markers, EpCAM + CK, were the most expressed biomarkers on CTCs in LC vs. HCC followed by AFP, EpCAM and CK.•The cell area of AFP was significantly higher in the LC group when compared with the HCC group (P value = 0.035).•CTCs cell area (EpCAM+CK+ AFP) performed well with an AUC of 0.92, in detecting early-stage and AFP-negative HCC and LC cases.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Equal author contribution.
ISSN:0973-6883
2213-3453
DOI:10.1016/j.jceh.2023.02.002